Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 20/20 | 0.64 |
| ▸ | KAT6A | Q92794 | 20/20 | 0.64 |
| ▸ | KAT6B | Q8WYB5 | 13/20 | 0.64 |
| ▸ | KAT5 | Q92993 | 13/20 | 0.64 |
| ▸ | KAT8 | Q9H7Z6 | 13/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26074584 | 1.00 | KAT7 (0.64) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL30545690 | 0.95 | KAT7 (0.60) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26076467 | 0.95 | KAT7 (0.60) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26073906 | 0.94 | KAT7 (0.56) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26077052 | 0.94 | KAT7 (0.60) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26074557 | 0.94 | KAT7 (0.59) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26076237 | 0.93 | KAT7 (0.57) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL30545724 | 0.93 | KAT7 (0.58) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL30545654 | 0.93 | KAT7 (0.58) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26076125 | 0.93 | KAT7 (0.58) | KAT7KAT6AKAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051343-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2025-02-13 | — | — | US | disclosed |
| EP-4499609-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12187732-B2 | Inhibitors of the myst family of lysine acetyl transferases | Isosterix, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| US-20230416260-A1 | Inhibitors of the MYST Family of Lysine Acetyl Transferases | Isosterix, Inc. | 2023-12-28 | — | — | US | disclosed |
| WO-2023192817-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051343-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | KAT7 4/4885KAT6A 1/4885KAT6B 2/4885 |
| US-20230416260-A1 | Inhibitors of the MYST Family of Lysine Acetyl Transferases | KAT6A, KAT6B, KAT2A | KAT7 4/4885KAT6A 1/4885KAT6B 2/4885 |
| US-12187732-B2 | Inhibitors of the myst family of lysine acetyl transferases | KAT6A, KAT6B, KAT2A | KAT7 4/4885KAT6A 1/4885KAT6B 2/4885 |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | KAT7 4/4885KAT6A 1/4885KAT6B 2/4885 |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | KAT6A, KAT6B, KAT2A | KAT7 4/4885KAT6A 1/4885KAT6B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.